FRAmework-01: A Three-Part Phase 3 Study of Sofetabart Mipitecan (Sofe-M) in Platinum-Resistant Ovarian Cancer (PROC), and Sofe-M plus Bevacizumab (Bev) in Platinum-Sensitive Ovarian Cancer (PSOC) (ESMO Asia 2026) - Oct 1, 2026 - Abstract #530TiP; Pres time: Dec 4, 2026; 05:15 PM - 06:15 PM; Location: Poster area (Exhibition); No abstract available
P3 data • Platinum resistant • Platinum sensitive • Oncology • Ovarian Cancer • Solid Tumor
|
|
Jung-Yun Lee; Xiaohua Wu; Roisin E. O'Cearbhaill; Bhavana Pothuri; Elena Ioana Braicu; Nicole Concin; Lauriane Eberst; Terri Pustilnik; Shoji Nagao; Yunong Gao; Fernando Galvez Montosa; Destin Black; Akira Kikuchi; Guiling Li; Susana Banerjee; Deepa Sachdeva; Monique Coersmeyer; Maarten Hulstijn; Isabelle L. Ray-Coquard; Kosei Hasegawa
|